Ares Capital Seeks Shareholder Approval to Issue Stock Below NAV
summarizeSummary
Ares Capital filed a definitive proxy statement seeking shareholder authorization to issue up to 25% of its common stock below Net Asset Value (NAV) over the next year, a recurring request providing capital flexibility.
check_boxKey Events
-
Shareholder Vote on Below-NAV Issuance
A Special Meeting of Stockholders is scheduled for August 13, 2026, to vote on authorizing the company to issue up to 25% of its common stock below Net Asset Value (NAV) per share.
-
Authorization for Capital Flexibility
This authorization provides Ares Capital with flexibility to raise capital for new investments, maintain regulatory debt-to-equity ratios, and pursue opportunistic acquisitions, which is critical for a BDC.
-
Potential Dilution Risk
If exercised, issuing shares below NAV would result in immediate dilution for existing shareholders who do not participate in such offerings.
-
Historical Precedent and Limited Use
The company has sought and received similar annual approvals for the past 17 years, using it only once in 2009 for an acquisition that was highly accretive to stockholders.
auto_awesomeAnalysis
Ares Capital is seeking shareholder authorization to issue up to 25% of its outstanding common stock at a price below its Net Asset Value (NAV) per share. This authorization, if approved, would be effective for a twelve-month period. For a Business Development Company (BDC) like Ares Capital, this flexibility is crucial for maintaining regulatory debt-to-equity ratios and accessing capital markets for new investment opportunities, especially given the recent Q1 2026 report of significant net unrealized losses on investments. While potentially dilutive for existing shareholders, the company notes this is a recurring annual request and has historically been used sparingly, primarily for accretive acquisitions during market volatility.
At the time of this filing, ARCC was trading at $18.94 on NASDAQ in the Unknown sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $17.40 to $23.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.